Internal Control · 2025
In this section9 topics
- Internal Control — Board Opinion1 item
- Adequacy & Appropriateness of the Internal Control System1 item
- Internal Control Deficiencies1 item
- Audit Committee & Auditor Observations2 items
- Opinion on the Head of Internal Audit2 items
- Appointment, Discharge & Transfer of the Head of Internal Audit2 items
- Related Party Transactions2 items
- Counterparties & Transactions3 items
- Policy & Future Trends3 items
Internal Control — Board Opinion
Summary of the Board's Opinion on Internal Control
The Company recognizes the utmost importance of having a good internal control system in accordance with the principles of Good Corporate Governance, including international guidelines and frameworks for internal control, to ensure that the Company can achieve its objectives. The Board of Directors has appointed three Audit Committee members who are able to perform their duties effectively and independently to review the internal control system and monitor the adequacy and appropriateness of internal controls in various areas to support business operations, effectiveness and efficiency in operations, prevention or mitigation of risks, potential damages, and to ensure that the financial statements are accurate and reliable, as well as compliance with laws, rules and regulations related to the Company's business operations and the relevant criteria of the Stock Exchange of Thailand and the Securities and Exchange Commission.
The Audit Committee has considered the qualifications of Proud Advisory Company Limited, an outsourced company, to be the internal auditor for 2025, with Mr. Prit Buapuern as the Head of Internal Audit. The Committee is of the opinion that they have sufficient qualifications to act as the Company's internal auditor, including independence in performing audits and assessing the adequacy of the internal control system and compliance with the Company's systems. The Audit Committee then proposed to the Board of Directors for appointment. The internal auditor has coordinated with personnel from all departments of the Company, followed up on improvements to the internal control system in accordance with the recommendations of the internal auditor, including preparing an internal control assessment and audit report of the Company, and presenting the report to the Audit Committee meeting directly and continuously on a regular basis. (Details regarding the qualifications of the Head of Internal Audit are shown in Annex 3)
Within the scope of authority, duties, and responsibilities of the Audit Committee, the Audit Committee is responsible for reviewing the Company to have an appropriate and effective internal control and internal audit system, as well as approving the appointment, transfer, or termination of the Head of Internal Audit.
Adequacy & Appropriateness of the Internal Control System
Internal Control Framework Used
| Framework | Detail |
|---|---|
| The Committee of Sponsoring Organizations of the Treadway Commission (COSO) | The Company recognizes the importance of having a good internal control system to ensure that the Company has an appropriate and adequate internal control system in accordance with the principles of good corporate governance in overseeing business operations. To ensure efficient, transparent, and auditable operations, as well as to prevent risks and damages that may occur to the Company and stakeholders, including the preparation and disclosure of complete, accurate, and reliable financial information and reports. In addition, the Board of Directors has established and reviewed the organization's risk management framework by assessing and analyzing both internal and external risk factors that affect the organization in order to implement them throughout the organization and use the organization's risk control systematically. The Board of Directors has assessed the adequacy of the Company's internal control system according to the SEC's internal control adequacy assessment form. By considering the internal control adequacy assessment form together with the internal control audit report, which was reviewed by Proud Advisory Company Limited, the Company's internal auditor, which is an external agency (Outsource), the results of the internal control adequacy assessment can be summarized according to the guidelines of The Committee of Sponsoring Organization of the Treadway Commission ("COSO"), which consists of 5 components, as follows: 1) Control Environment 2) Risk Assessment 3) Control Activities 4) Information & Communication 5) Monitoring Activities From the assessment of the adequacy of the Company's internal control system, it was found that the Company has a good, appropriate, and adequate internal control system to operate in accordance with the organization's objectives. The details of the internal control adequacy assessment are as follows: The audit results have not revealed any material weaknesses from the assessment of the Company's internal control system, covering all 5 main components, which have been reviewed by the Audit Committee. In the past year, the auditors and the internal audit unit did not have any significant observations regarding internal control deficiencies. The Audit Committee and the Board of Directors have considered and are of the opinion that the Company's internal control system is adequate and appropriate for the size and nature of the Company's business, in accordance with relevant laws and regulations, and in accordance with the principles of good corporate governance (Good Corporate Governance) and compliance with the established internal control system. In addition, the Company has allocated sufficient personnel to effectively implement the internal control system. |
Internal Control Deficiencies
Number of Deficiencies
| Metric | Current Year | Previous Year | Two Years Ago |
|---|---|---|---|
| Total number of internal control system deficiencies (cases) | 0 | 0 | 0 |
Audit Committee & Auditor Observations
Audit Committee's Opinion Differs from the Board's
No
Auditor Has Observations on Internal Control
No
Opinion on the Head of Internal Audit
Head of Internal Audit
3160
Audit Committee's Opinion on the Head of Internal Audit
The Audit Committee has appointed an internal auditor from Proud Advisory Co., Ltd., an external firm with appropriate qualifications, to serve as the Company’s internal auditor. The appointment was made based on the adequacy of personnel, as well as the experience, expertise, and independence of the internal auditor. The internal auditor is responsible for reviewing the operations of each department within the Company in accordance with the guidelines for assessing the adequacy of the internal control system as established by the Company. Additionally, the annual internal audit plan is prepared and submitted to the Audit Committee for consideration and approval, leveraging independence and experience in internal auditing.
Appointment, Discharge & Transfer of the Head of Internal Audit
Requires Audit Committee Approval
Yes
Description
The appointment, removal, and transfer of the Head of Internal Audit shall be subject to consideration by the Audit Committee at every instance and subsequently proposed to the Board of Directors for approval.
In the event that Proud Advisory Co., Ltd., an external (outsourced) service provider, with Mr. Parit Buapuean serving as the Head of Internal Audit as assigned by the Audit Committee, is deemed to lack the appropriate qualifications to perform the duties of the Company’s internal auditor, or lacks independence in carrying out audit activities and assessing the adequacy of internal control systems and compliance with the Company’s policies, or performs duties inefficiently or ineffectively, the Head of Internal Audit may be removed, transferred, or terminated. In such cases, the Audit Committee shall propose the matter to the Board of Directors for approval.
Related Party Transactions
Introduction
The Company had related party transactions with persons/juristic persons who may have conflicts of interest during the accounting period ended 31 December 2025, as follows:
Has Related Party Transactions
Yes
Counterparties & Transactions
Monetary Unit
1
Counterparties with Potential Conflicts
| Name | Person / Juristic Person | Type of Business | Nature of Relationship | As of Date (YYYY-MM-DD) |
|---|---|---|---|---|
| Mr. Choladhis Sinrachtanant | Person | Director / Chief Executive Officer / Authorized Director / 0.40 percent shareholder | 2025-12-31T00:00 | |
| Dr. Chaiyot Denariyakul | Person | Director / Hospital Director / 0.77 percent shareholder | 2025-12-31T00:00 | |
| Dr.Kongsak Techawibunphon | Person | Director / Chief Operating Officer / 0.52 percent shareholder | 2025-12-31T00:00 | |
| Cdr. Suwannee Jirayangyuen | Person | Director / Deputy Chief Executive Officer / Authorized Director / 22.86 percent shareholder | 2025-12-31T00:00 | |
| Suisa thaichinda | Person | Director / 0.01 percent shareholder | 2025-12-31T00:00 | |
| Thanachak Sinrachatanant | Person | Director / Authorized Director / 0.11 percent shareholder | 2025-12-31T00:00 | |
| Asst.Prof.Dr. CHOLADHIS SINRACHTANANT ,Mr. CHAIYOT DENARIYAKUL , Cdr. SUWANNEE JIRAYANGYUEN , Mr. KONGSAK TECHAWIBUNPHON , Ms. SUNISA THAICHINDA ,Mr.THANACHAK SINRACHTANANT | Juristic Person | medical services | Group of physicians who serve as directors and executives and are considered related persons. | 2025-12-31T00:00 |
Transactions by Counterparty
| Transactions |
|---|
| 37493835.32 · Necessity: The Company requires the expertise and experience of the following six physicians to perform medical procedures and provide services to patients according to their respective specialties: Asst.Prof.Dr. CHOLADHIS SINRACHTANANT – Procedural Physician Cdr. SUWANNEE JIRAYANGYUEN – Pre-procedure Assessment Physician Mr. CHAIYOT DENARIYAKUL– Procedural Physician Mr. KONGSAK TECHAWIBUNPHON – Anesthesiologist Ms. SUNISA THAICHINDA– Dermatology and Aesthetic Physician Mr.THANACHAK SINRACHTANANT – Pre-procedure Assessment Physician The Company pays physician fees at rates comparable to those paid to other physicians in the hospital, in accordance with the Company’s physician fee policy. · Description: Annual physician fees , cost of service · As of yesteryear: 54409685.05 · Nature of transaction: The Company pays remuneration in the form of physician fees. · Audit committee opinion: The transaction is necessary and reasonable as the Company pays such remuneration at rates comparable to those paid to other physicians in the hospital, in accordance with the Company’s physician fee policy. · As of year before yesteryear: 116300933.01 · 4785569.76 · Necessity: The transactions are necessary and reasonable for utilizing the expertise and experience of the six physicians in performing medical procedures for patients according to their respective specializations. The remuneration paid is at a rate comparable to that of other physicians in the hospital, in accordance with the policy on physician fee determination. · Description: Accrued physician fees payable represent expenses incurred in December and paid in January. For accounting purposes, they are classified as other current payables. · As of yesteryear: 3931166.35 · Nature of transaction: Accrued physician fees payable · Audit committee opinion: The transaction is necessary and reasonable as the Company pays such remuneration at rates comparable to those paid to other physicians in the hospital, in accordance with the Company’s physician fee policy. · As of year before yesteryear: 8386619.0 |
| 2276161.2 · Necessity: This is due to their knowledge, experience, and expertise in the Aesthetic and Anti-Aging Medicine Center. · Description: The consultancy fee for the Aesthetic and Anti-Aging Medicine Department is an administrative expense. · As of yesteryear: 0.0 · Nature of transaction: Consulting fee · Audit committee opinion: The Audit Committee has considered and is of the opinion that such transaction is beneficial to the Company in expanding the Aesthetic and Anti-Aging Medicine Center. The price and conditions are in accordance with mutually agreed terms. · As of year before yesteryear: 0.0 · 60945.2 · Necessity: To help generate revenue for the Aesthetic and Anti-Aging Medicine Center. · Description: The annual commission arises from revenue generation for the Aesthetic and Anti-Aging Medicine Department and is considered a distribution cost · As of yesteryear: 0.0 · Nature of transaction: Commission fee · Audit committee opinion: he Audit Committee has considered and is of the opinion that such transaction is beneficial to the Company in expanding its customer base, with the transaction conducted at mutually agreed rates. · As of year before yesteryear: 0.0 |
Policy & Future Trends
Introduction
The Board of Directors’ Meeting No. 1/2023 (Public Company) held on 23 February 2023, the Board considered and approved the Company’s policy on related party transactions. The policy is reviewed annually to ensure that such transactions are conducted properly and in compliance with applicable laws and regulations.The Company is aware of its duty to comply with the rules regarding related party transactions or connected transactions as specified by the Stock Exchange, the Capital Market Supervisory Board, and the Securities and Exchange Commission.
Policy, Measures & Approval Process
There are criteria and procedures for conducting related transactions. or related transactions as follows:
-Consideration of connected transactions. The Company will use the same price criteria and trade agreements as those used with general customers. As for the list of giving or receiving financial assistance It must be necessary and reasonable. And there must be fair terms and conditions. and create the greatest benefit to the company
-In the case where there is no such price criteria for reference. The Company will consider comparing the price of products or services with external prices under the same or similar conditions.
-The Company may make use of the reports of independent assessors appointed by the Company to compare prices for key inter-operation transactions to ensure that such prices are reasonable and in the best interests of the Company.
-Directors, executives, or related persons may transact with the company or subsidiary only after such transaction has been approved by the company's shareholder meeting. Unless the transaction is a commercial agreement in the same manner that a reasonable person would deal with a normal contracting party in the same situation with trade bargaining power without influence from his or her status as a director, executive, or person with relevant, as the case may be, and is a commercial agreement approved by the committee or in accordance with the principles approved by the committee.
-If the company has related transactions or other connected transactions. that meets the requirements of the Stock Exchange Capital Market Supervisory Board and the Securities and Exchange Commission The company must strictly comply with such requirements.
-The company must disclose information about transactions that may have conflicts of interest. Related items or related transactions According to the rules of the Stock Exchange The Capital Market Supervisory Board and the Securities and Exchange Commission determine It is disclosed in the annual information disclosure form and annual report or any other report form and information on related transactions has been disclosed to the Stock Exchange. According to the regulations of the Stock Exchange as well as transactions related to the company. According to accounting standards.
-There must be a review of connected transactions according to the audit plan, with the internal audit department reporting to the Audit Committee. There are measures to control, inspect, and oversee that there is a random review of actual transactions, correctness, and compliance with the contract or policy or conditions specified.
Future Trends in Related Party Transactions
Related transactions that may occur in the future The company will comply with the laws regarding securities and the stock exchange and the regulations, announcements, orders or requirements of the Stock Exchange of Thailand. Those who may have conflicts or have interests in related transactions will not have the right to vote on such related transactions. Such related transactions must be considered according to the company's related transactions policy. According to the resolution of the Board of Directors' Meeting No. 1/2023 (Public Company) on February 23, 2023, in order to comply with the nature of normal trade operations and be a market price that can be compared or referenced with the price conditions at the company. Acting with third parties other than this, entering related transactions must be considered for necessity and appropriateness of price by the Audit Committee. However, if the audit committee does not have expertise in related transactions that may occur The Company will consider having an independent evaluator, independent specialist or the Company's auditor give an opinion on such related transactions for the Audit Committee to make decisions and provide opinions to the Board of Directors or shareholders, depending on case.

